Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note ...

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw strong trading volume on Friday . 413,080 shares were traded during trading, a decline of 47% from the previous session’s volume ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

Capricor Therapeutics (CAPR) stock gains as the company completes the U.S. marketing application for lead drug deramiocel in ...

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...

US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...